SA TB Guidelines The interface with Advanced Clinical Care
|
|
- Shavonne Ball
- 6 years ago
- Views:
Transcription
1 SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop on Advanced Clinical Care ICC Durban 6 October 2016
2 Presentation Outline Diagnostic algorithm for DR and DS TB Retreatment TB: Revised definitions and treatment regimen ART initiation in TB patients Special considerations: Aluvia with TB treatment Atazanavir in TB Ethambutol in Renal failure Moxifloxacin and streptomycin indications TB prevention in HIV infected patients
3 Currently available TB Diagnostic tests
4 Which initial TB diagnostic test does WHO recommend for HIV + people with suspected TB? 1. Smear Microscopy 2. Xpert MTB/RIF 3. Culture
5 Which initial TB diagnostic test does WHO recommend for HIV + people with suspected TB? 1. Smear Microscopy 2. Xpert MTB/RIF 3. Culture
6 Where GeneXpert (GXP) is available, culture may still be required for: 1. HIV positive TB suspects, who have a negative GXP test 2. TB cases diagnosed as Rifampicin(Rif) resistant on GXP for susceptibility testing of other drugs 3. Despite a Rif susceptible result, the patient is failing treatment and treatment adherence is good and thus resistance to drugs other than Rif is suspected 4. All of the above
7 TB SUSPECTS TB and DR-TB contacts, non-contact symptomatic individuals, re-treatment after relapse, failure and default Collect one sputum specimen at the health facility under supervision GXP positive Rifampicin susceptible GXP positive Rifampicin resistant GXP positive Rifampicin unsuccessful GXP negative GXP unsuccessful Treat as TB Start on Regimen 1 Send one specimen for microscopy Treat as MDR-TB Refer to MDR-TB facility Treat as TB Start on Regimen 1 Collect one specimen for microscopy Culture & DST / LPA HIV positive HIV negative Collect one sputum specimen for a repeat GXP Collect one specimen for culture and LPA or culture and DST (for R and H) Treat with antibiotics and review after 5 days Do chest x-ray Treat with antibiotics Follow up with microscopy Collect one specimen for microscopy, culture and DST for Rifampicin, Isoniazid, fluoroquinolone and Aminoglycoside Poor response to antibiotics Clinically TB TB on chest x-ray LPA/ DST results Resistant to R and H/ R only Good response No further follow up Advise to return when symptoms recur Poor response Consider other diagnosis Refer for further investigation Follow up with microscopy and culture Treat as TB Start on Regimen 1 Review culture results Treat as MDR-TB Refer to MDR-TB Unit
8 Where GeneXpert (GXP) is available, culture may still be required for: 1. HIV positive TB suspects, who have a negative GXP test 2. TB cases diagnosed as Rifampicin(Rif) resistant on GXP for susceptibility testing of other drugs 3. Despite a Rif susceptible result, the patient is failing treatment and treatment adherence is good and thus resistance to drugs other than Rif is suspected 4. All of the above
9 Streptomycin is indicated for: 1. All categories of DS TB 2. All categories of retreatment TB 3. For patients that cannot tolerate first line TB medication 4. All of the above 5. None of the above
10 TB SUSPECTS TB and DR-TB contacts, non-contact symptomatic individuals, re-treatment after relapse, failure and default Collect one sputum specimen at the health facility under supervision GXP positive Rifampicin susceptible GXP positive Rifampicin resistant GXP positive Rifampicin unsuccessful GXP negative GXP unsuccessful Treat as TB Start on Regimen 1 Send one specimen for microscopy Treat as MDR-TB Refer to MDR-TB Unit Treat as TB Start on Regimen 1 Collect one specimen for microscopy Culture & DST / LPA HIV positive HIV negative Collect one sputum specimen for a repeat GXP Collect one specimen for culture and LPA or culture and DST (for R and H) Treat with antibiotics and review after 5 days Do chest x-ray Treat with antibiotics Follow up with microscopy Collect one specimen for microscopy, culture and DST for Rifampicin, Isoniazid, fluoroquinolone and Aminoglycoside Poor response to antibiotics Clinically TB TB on chest x-ray LPA/ DST results Resistant to R and H/ R only Good response No further follow up Advise to return when symptoms recur Poor response Consider other diagnosis Refer for further investigation Follow up with microscopy and culture Treat as TB Start on Regimen 1 Review culture results Treat as MDR-TB Refer to MDR-TB Unit
11 Streptomycin is indicated for: 1. All categories of DS TB 2. All categories of retreatment TB 3. For patients that cannot tolerate first line TB medication 4. All of the above 5. None of the above
12 TB Treatment if unable to treat with standard first line Rx Missing drug Possible regimen Duration of treatment INH Rifampicin Rifampicin/INH Moxifloxacin/ rifampicin/ ethambutol Moxifloxacin/ INH/ ethambutol Moxifloxacin/ ethambutol/ streptomycin 12 months ±PZA in intensive phase 18 months(pza or streptomycin in intensive phase) 18 months PZA Rifampicin/INH/ ethambutol Nine months
13 Mechanism of TB treatment associated DILI Drug Mechanism Clinical picture RIF PZA INH Dose-dependent interference with bilirubin uptake ±hypersensitivity reaction Dose-dependent and idiosyncratic hepatotoxicity Free radical generation: toxic to hepatocytes Onset: Transient, early in treatment Subclinical, Jaundice without hepatocellular damage, Unconj Bil. May potentiate hepatotoxic effects of other drugs. Hypersensitivity reactions with eosinophilia and liver injury or granulomatous hepatitis. More damage in liver with pre-existing disease. Onset: Within weeks to months. Rechallenge does not always elicit a rapid recurrence of hepatotoxicity **Alcohol consumption doubles rate of probable INH hepatitis
14 Definition of DILI SA HIV Clinician s Society DILI guidelines: ALT level > 120 IU/L and symptomatic (Nausea, vomiting, abdominal pain, jaundice) or ALT level >200 IU/L and asymptomatic or Total serum bilirubin concentration > 40 umol/l
15 Risk factors for DILI Modifiable HIV infection Hepatitis B Surface antigen positivity Hepatitis C coinfection Malnutrition Hypo-albuminaemia Abnormal baseline ALT Alcohol use Non-modifiable Underlying liver disease Age >35 years Childhood Slow acetylator status Female sex
16 Management of TB DILI Limited data Most guidelines are based on expert opinion
17 Principles of TB DILI management Moderate to severe liver damage STOP drugs Investigate for other causes of hepatitis Confirm the diagnosis of TB Green card Intensive phase/ continuation phase Search for pending TB culture results Re-investigate for TB
18 TB Drug Rechallenge in DILI If patient presented in liver failure: TB drug re-challenge is not recommended Otherwise, re-challenge Rates of DILI recurrence in re-challenge is 12 % Rechallenge method: Regimen Rechallenge vs Sequential Drug Rechallenge - latter in full doses vs incremental doses RCT data on Rates of DILI recurrence by type of Rechallenge method: Regimen Rechallenge (14%) vs Sequential Drug Rechallenge in full (10%) vs incremental (9%) doses
19 Case 1 Miss HS is a HIV positive 34 year old female. She is clinically stable on an FDC. She is diagnosed with TB Lymphadenopathy based on AFB demonstrated in LN aspirate following a 2 month duration of fever and LOA. She tolerates TB Rx well and has resolution of constitutional symptoms. On routine LFT is as follows: ALT= 79 IU/L Normal Total bilirubin AST= 60 IU/L Normal ALP and GGT
20 What is the most appropriate management? 1. Refer for admission, Stop TB treatment, Stop ART 2. Continue TB treatment and ART, discharge from follow up 3. Continue TB treatment and ART, repeat ALT and Bili in 1 week 4. Continue TB treatment and ART, repeat ALT and Bili daily
21 What is the most appropriate management? 1. Refer for admission, Stop TB treatment, Stop ART 2. Continue TB treatment and ART, discharge from follow up 3. Continue TB treatment and ART, repeat ALT and Bili in 1 week 4. Continue TB treatment and ART, repeat ALT and Bili daily
22 Mild DILI Clinically well ALT <200 and Total Bili <40 Continue TB drugs Continue ART if already initiated Repeat ALT and Bili in 1 week If ALT and bili improving or normal then stop Lab monitoring If ALT and Bili continue to rise, treat as moderate or severe DILI
23 Moderate DILI Clinically well ALT> 200 irrespective of Total Bili Stop TB regimen Discontinue Bactrim prophylaxis and other hepatotoxic drugs Start ETH/ MOX/ STR if treatment necessary Stop ART unless on a stable ART regimen for > 6 months Repeat ALT and Bili in 3 (Inpt) or 7 (Outpt) days When ALT < 100 and Bili is normal, attempt rechallenge
24 TB Drugs in Renal failure INH, rifampicin, PZA : biliary excretion normal doses Streptomycin and ethambutol : can maintain at reduced dose monitor for uveitis Safest regimen: INH, Rifampicin, pyrazinamide X 4 months followed by INH and Rifampicin x 2 months
25 Managing TB treatment Interruption Less than 1 month: extend treatment for the number of days that patient did not take treatment 1-2 months missed: do genexpert Sensitive: add number of days that patient did not take treatment. Resistant: stop treatment: refer to MDR-TB unit More than 2 months missed (loss to follow up) do genexpert Sensitive : restart treatment Resistant : refer MDR-TB
26 Integration of TB HIV Services Screening for TB and HIV at same visit Early initiation of ARVs Co-management of Drug toxicities common to both Consideration of Drug interactions Early detection and management of TB IRIS Initiation of INH prophylaxis
27 In TB co-infection, start with TB treatment first, followed by ART as soon as possible and within 8 weeks If CD4 <50 cells/μl initiate ART within 2 weeks of starting TB treatment, when the patient s symptoms are improving and TB treatment is tolerated If CD4 >50 cells/μl initiate ART within 2-8 weeks of starting TB treatment In cryptococcal or TB meningitis: Defer ART initiation for 4-6 weeks
28 Integrated service delivery TB service One-stop service HIV service TB screening NO To Referral HIV testing ART CPT Condoms HIV and TB Services provided together ART TB diagnosis and treatment IPT TB diagnosis TB treatment TB contact tracing NO To Referral Partially integrated Co-located Adjacent Partially integrated Models for integrated TB and HIV services delivery Source: WHO
29 Concerns of co-treating TB and HIV Overlapping Toxicity Drug Interactions IRIS
30 What are the overlapping drug toxicities with TB treatment and ARVs? 1. Liver Injury 2. Rash 3. Psychosis 4. All of the above
31 Overlapping Toxicities with co-rx of HIV and TB Side-effect Antiretroviral drug TB Therapy Nausea & vomiting Hepatitis Peripheral neuropathy Didanosine, Zidovudine, Ritonavir Nevirapine Efavirenz Stavudine Didanosine Pyrazinamide Rifampicin Isoniazid Pyrazinamide Isoniazid Rash Nevaripine Efavirenz Rifampicin Isoniazid Pyrazinamide Ethambutol Psychosis EFV INH/Ethambutol
32 What are the overlapping drug toxicities with TB treatment and ARVs? 1. Liver Injury 2. Rash 3. Psychosis 4. All of the above
33 Case 2 Mrs AA is HIV + since She was initially started on TDF / 3TC and EFV. In 2014, she was changed to ABC / 3TC and Alluvia due to treatment failure. She now presents with night sweats, loss of appetite and abdominal pain. The Gene Xpert test on ascitic fluid is positive for Rif sensitive MTB
34 How to do you manage further? 1. Start TB Rx, double the dose of Aluvia immediately 2. Start TB Rx, double the dose of Aluvia over 2 weeks 3. Double the dose of Aluvia over 2 weeks then start TB Rx
35 How to do you manage further? 1. Start TB Rx, double the dose of Aluvia immediately 2. Start TB Rx, double the dose of Aluvia over 2 weeks 3. Double the dose of Aluvia over 2 weeks then start TB Rx
36 Mrs AA improves on TB Rx and completes the course. Her symptoms and signs have resolved, and her exit sputum is negative for AFB. How do you manage further? 1. Reduce Aluvia dose to 2T bd immediately 2. Continue TB Rx for two weeks longer 3. Continue the double dose (4T bd) of Aluvia until 2 weeks after TB Rx is completed
37 Mrs AA improves on TB Rx and completes the course. Her symptoms and signs have resolved, and her exit sputum is negative for AFB. How do you manage further? 1. Reduce Aluvia dose to 2T bd immediately 2. Continue TB Rx for two weeks longer 3. Continue the double dose (4T bd) of Aluvia until 2 weeks after TB Rx is completed
38 Case 3 Mr E has been on a second line regimen for a year. His regimen includes AZT/3TC/ATZ/rit because he had severe diarrhoea whilst on Aluvia. He now presents with fever and productive cough. His sputum Gene Xpert is positive for Rif sensitive MTB.
39 How do you manage further? 1. Commence TB treatment immediately 2. Double the dose of Atazanavir as you do for Aluvia 3. Atazanavir may not be given to patients on TB treatment. Refer to specialist 4. Stop the ART, treat TB, then restart ART
40 How do you manage further? 1. Commence TB treatment immediately 2. Double the dose of Atazanavir as you do for Aluvia 3. Atazanavir may not be given to patients on TB treatment. Refer to specialist 4. Stop the ART, treat TB, then restart ART
41 Drug Interactions: 1. RIF and EFV Previously reported that Rif caused a 30% decrease in EFV trough concentrations, particularly in patients >50kg. An increase in EFV dose recommended by FDA (USA) Later reports clearance of EFV is reduced in black African patients, due to CYP enzyme polymorphisms (therefore drug levels actually increased by 30-50%) No increase in EFV dose recommended in SA
42 2. RIF and PI PI metabolized by CYP 3A4: induced by Rifampicin and inhibited by Ritonavir Significant reduction of plasma drug levels of most PI s, except Ritonavir LPV/r (Aluvia): Ritonavir boosted Lopinavir (400/100mg) Increase Ritonavir to 400mg daily to overcome the enzyme induction double Aluvia dose Usual 2T BD, increased to 3T BD for 1 wk then 4T BD Maintain escalated dose of PI until 2 wks after TB Rx completion Rif accelerated Atazanavir/r metabolism, cannot be overcome by boosting with Ritonavir Referral to higher centre to change PI or change Rifampicin to Rifabutin
43 TB IRIS TB diagnosed & treatment started before ART initiation No TB diagnosis before ART initiation ART Initiation Clinical deterioration of TB as a result of ART-induced immune recovery = Paradoxical TB IRIS Atypical inflammatory presentation of TB as a result of ART-induced immune recovery = Unmasking IRIS Lawn Expert Rev Anti Infect Ther, 2011.
44 TB IRIS incidence, risk factors and outcomes Unmasking TB IRIS Incidence 4.8% (most common ) Paradoxical TB-IRIS Incidence 18% Onset 14 days after ART initiation in 48% Hospitalisation 25% Mortality 7%, death attributed to TB IRIS 2% Increased mortality in CNS IRIS Risk Factors: Low CD4 count, Short interval between TB treatment and ART, Disseminated TB
45 TB IRIS Management Double-blind, placebo-controlled RCT Intervention: Prednisone 1.5mg/kg/day x 2 wks then 0.75mg/kg/day x 2 wks Primary outcome = hospital days Findings: Steroid arm - fewer days in hospital and fewer procedures. IRIS associated mortality same in both arms, except CNS disease Excl other causes of patient deterioration: MDR TB etc
46 What are the current guidelines for IPT for patients on ART? months IPT for all patients months IPT for all patients 3. 6 months IPT for all patients months IPT for TST positive, 12 months for TST negative, 6 months for TST unknown
47 INH Prophylaxis
48 What are the current guidelines for IPT for patients on ART? months IPT for all patients months IPT for all patients 3. 6 months IPT for all patients months IPT for TST positive, 12 months for TST negative, 6 months for TST unknown
49 Questions Are patients eligible for more IPT post TB therapy completion? 1. Yes: can be started immediately after TB treatment in all patients 2. No: patients no longer at risk for TB, having just completed TB treatment 3. Yes: can be started immediately after TB treatment but only in patients with documented bacteriologic cure
50 Questions Are patients eligible for more IPT post TB therapy completion? 1. Yes: can be started immediately after TB treatment in all patients 2. No: patients no longer at risk for TB, having just completed TB treatment 3. Yes: can be started immediately after TB treatment but only in patients with documented bacteriologic cure
51 Summary Diagnostic algorithm for DR and DS TB Retreatment TB: Revised definitions and treatment regimen ART initiation in TB patients Special considerations: Aluvia with TB treatment Atazanivir in TB Ethambutol in Renal failure Moxifloxacin and streptomycin indications TB prevention in HIV infected patients
52 Acknowledgements This training was supported by the Grant or Cooperative Agreement Number U2G GH001142, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the presenters and do not necessarily represent the official views of the U.S. Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015
More informationMANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo
MANAGEMENT OF DILI in TB/HIV coinfected patients Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo ANTI-TB drugs Groups Drugs Group 1: First-line oral drugs Ethambutol (Emb) Pyrazinamide(PZA) Isoniazid (INH)
More informationHIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationAnri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town
Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town Since March 2008 26 700 Queries to date 450 Queries per month South Africa:
More informationTB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011
TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationImmune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela
Immune Reconstitution Inflammatory Syndrome Dr. Lesego Mawela TOPICS FOR DISCUSSION IRIS Case Epidermiology Pathogenesis of IRIS Risk factors for IRIS Epidemiology of IRIS Health system burden of IRIS
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationTB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More informationThe diagnosis, management and prevention of HIV-associated tuberculosis
REVIEW The diagnosis, management and prevention of HIV-associated tuberculosis S Wasserman, 1 MB ChB, MMed, FCP (SA), Cert ID (SA) Phys; G Meintjes, 1,2 MB ChB, FRCP (Glasg), FCP (SA), Dip HIV Man, MPH,
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationTB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline
TB Grand Rounds Reynard McDonald, MD & Henry Fraimow, MD January 30, 2007 Outline Overview of 2006 ATS statement regarding hepatotoxicity of anti-tb therapy Case examples highlighting management of patients
More informationHIV/TB Co infection TB Clinical Intensive October 11, 2018
HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationClinical guidelines for the management of HIV/AIDS in adults and adolescents 15 years. SAHIVCS - CME 13/06/15 DR.Henry Sunpath
Clinical guidelines for the management of HIV/AIDS in adults and adolescents 15 years SAHIVCS - CME 13/06/15 DR.Henry Sunpath 1 Introduction What is new? Goals and objectives Guiding principles HIV continuum
More information6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None
TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard
More informationOverview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions
202/03/28 Isoniazid preventive therapy: evidence for safety and efficacy Clinician s course Gavin Churchyard/ Liesl Page-Shipp 6 March 202 Overview Treatment of latent TB infection Meta-analysis 36 months
More informationDrug-sensitive and drugresistant
CHAPTER 7 87 Drug-sensitive and drugresistant tuberculosis Tuberculosis Types of active TB disease Five I s to reduce the burden of TB in PLHIV Clinical presentation of extrapulmonary TB Evaluating for
More informationDifference of opinion? Michelle Moorhouse 24 Sep 2014
Difference of opinion? Michelle Moorhouse 24 Sep 2014 Meet NN 52 years, female Nurse in pre-art clinic Referred Feb 2012 by dermatologist History of severe reactions to ART Erythema and bullous eruptions
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationIsoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children. Réghana Taliep
Isoniazid Preventive Therapy (IPT) in HIV-Infected and Uninfected Children Réghana Taliep Background Tuberculosis (TB) is a common complication and leading cause of death in HIV infection HIV is the strongest
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationMonica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale
Randomized Trial of lsoniazid as Secondary Prophylaxis for Prevention of Recurrent Pulmonary Tuberculosis in HIV-positive Patients After One Episode of Tuberculosis Monica Manandhar A. Study Purpose and
More informationThe NEW ARV Guidelines FAQs
The NEW ARV Guidelines FAQs Dr Madeleine Muller MBChB (Pret).MRCGP(Lon).Dip Hiv Man IYDSA Clinical Advisor Acknowledgments IYDSA for materials and support NDOH for slides CDC our funder HIV Clinician Society
More informationLTBI in Special Populations John Nava, MD October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationSouth African HIV Clinicians Society Managing adult treatment through case study discussion
South African HIV Clinicians Society Managing adult treatment through case study discussion Jade Mogambery Grey s Hospital, Pietermaritzburg Infectious Diseases Unit Referral summary 20-year-old male HIV
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationTB and HIV co-infection including IRIS
TB and HIV co-infection including IRIS Richard Lessells SAHCS Conference 2018 Clinical scenario 1 36-year-old male Presents with cough, fever & weight loss HIV test positive (new diagnosis) Sputum Xpert
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationManaging the Patients Response to TB Treatment
Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has
More informationDR-TB Patient Treatment Log Book
REPUBLIC OF KENYA MINISTRY OF HEALTH DR-TB Patient Treatment Log Book Patient Name: Patient Reg. No.: VERSION 2016 DR-TB treatment outcome summary Outcome Mark one Date Cured Died Failed Defaulted Transferred
More informationPaediatric ART: eligibility criteria and first line regimens. (revised) Dave le Roux 13 August 2016
Paediatric ART: eligibility criteria and first line regimens (revised) Dave le Roux 13 August 2016 Outline Eligibility criteria for starting ART Evolving evidence for earlier ART W Cape, National, WHO
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationTB in Prisons and Jails Albuquerque, New Mexico November 28, 2012
TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationTuberculosis: update 2013
Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference
More informationMy heart is racing. Managing Complex Cases. Case 1. Case 1
Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationInformation Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis
Information Note WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis In order to ensure that the upcoming comprehensive revision of WHO policies on treatment
More informationAnti Tuberculosis Medications: Side Effects & adverse Events
Anti Tuberculosis Medications: Side Effects & adverse Events Diana Fortune, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Diana Fortune, RN,
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationGary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!!
Gary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!! DECLARATION No relevant conflicts of interest to declare OVERVIEW Burden of disease & epidemiology Pathogenesis (not
More informationClinical Case Scenario. HIVeEducation Workshop, Sint Maarten 2009
Clinical Case Scenario HIVeEducation Workshop, Sint Maarten 2009 Background Mrs. S is a 34 year-old woman who was referred from the VCT center after testing HIV positive three weeks ago. Her husband recently
More informationAn Update on TB and OI prophylaxis
An Update on TB and OI prophylaxis Dr Nithendra Manickchund Department of Infectious Diseases Nelson R. Mandela School of Medicine University of KwaZulu-Natal TB Infection Tuberculosis (TB) infection occurs
More informationTB and Comorbidities Adriana Vasquez, MD April 12, 2018
TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:
More informationEswatini NTCP and Baylor Global TB Pilot Project on DR-TB Contact Management. WHO Child and Adolescent Working Group October 2018 Dr Debrah Vambe
Eswatini NTCP and Baylor Global TB Pilot Project on DR-TB Contact Management WHO Child and Adolescent Working Group October 2018 Dr Debrah Vambe Objectives Review current status of DR and DS-TB care and
More informationStandard TB Treatment
Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationIPT IMPLEMENTATION- SWAZILAND EXPERIENCE
IPT IMPLEMENTATION- SWAZILAND EXPERIENCE Gugu Mchunu-National TB/HIV coordinator Programmatic Management of Latent TB infection consultation meeting Seoul, Republic of Korea,27-28 APRIL,2016 TB Epidemiology
More informationTuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009
TB in the Correctional Setting Collinsville, Illinois April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD
More informationDr Francis Ogaro MTRH ELDORET
Dr Francis Ogaro MTRH ELDORET TB in children often severe, disseminated and can progress rapidly and with poor outcome TB diagnosis in children has relied on clinical, imaging, microscopy and TST findings.
More informationDebbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas
Managing and Monitoring Side Effects and Toxicities of Anti TB Therapy Debbie Onofre, RN, BSN March 18, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM
ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM The form and content of the explanatory note is to: Inform those responsible for completing the DMR 164 Reporting Form - as to
More informationOfficial American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines:
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis OBJECTIVES
More informationTB or Not TB That is the Question. Yunus Moosa Department of Infectious Diseases UKZN
TB or Not TB That is the Question Yunus Moosa Department of Infectious Diseases UKZN Case: Mr. DN 42 yr. Male HIV on ART since 2006 and HPT - perindopril 1/12 prior to admission -fever, cough and cervical
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationTB/HIV management survey
TB/HIV management survey! Baseline audit in parallel with guidelines development process! Survey of clinician opinion and practice! Data collection from October 2004 to January 2005! Data was received
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationAdvanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF
Advanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF Mozambique Mozambique Mozambique Mozambique Preventing mortality MSF hospital, Kinshasa,
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationTB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:
TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationTB in Children. Rene De Gama Block 10 Lectures 2012
TB in Children Rene De Gama Block 10 Lectures 2012 Contents Epidemiology Transmission and pathogenesis Diagnosis of TB TB and HIV Management Epidemiology The year 2000 8.3 million new TB cases diagnosed
More informationThe New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations
Workshop to accelerate the implementation of the Three Is for HIV/TB and earlier initiation of ART in Southern Africa, March 14-18, 2011, Johannesburg, South Africa. The New WHO guidelines on intensified
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationDisclaimer. Programmatic Challenges in the care of HIV and TB co infection. Overview. Goal
Disclaimer Programmatic Challenges in the care of HIV and TB co infection Maunank Shah M.D. Johns Hopkins University Nov ember 17, 2011 This presentation will ask many questions for which I don t have
More information11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction
SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More informationHyperbilirubinemia during atazanavir treatment in people living with HIV (PLHIV), Sri Lanka. Abstract
Hyperbilirubinemia during atazanavir treatment in people living with HIV (PLHIV), Sri Lanka. D.I.Rajapaksha 1, A.Azraan 2, L.I.Rajapaksa 3 Abstract Introduction: Atazanavir (ATV) is an antiretroviral drug
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationHIV and TB coinfection: Updates. Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University
HIV and TB coinfection: Updates Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University Learning objectives Identify the optimal timing of antiretroviral therapy in patients
More informationNATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis
NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature:
More information